Real-time context
Follow the latest analyst actions, insider and institutional activity, earnings, dividends, price moves, and company filings.
Rating Change Truist Securities analysts reiterated a Buy rating on Willis Towers Watson Public Limited Company (NASDAQ:WTW) on July 31, 2026. Market Context Willis Towers Watson…
Read moreRating Change Wells Fargo analysts reiterated a Overweight rating on Willis Towers Watson Public Limited Company (NASDAQ:WTW) on July 31, 2026. Market Context Willis Towers Watson…
Read moreRating Change Mizuho analysts reiterated a Outperform rating on SoFi Technologies, Inc. (NASDAQ:SOFI) on July 31, 2026. Market Context SoFi Technologies, Inc.
Read moreRating Change BTIG analysts reiterated a Buy rating on Live Nation Entertainment, Inc. (NYSE:LYV) on July 31, 2026. Market Context Live Nation Entertainment, Inc.
Read moreRating Change Guggenheim analysts reiterated a Buy rating on Live Nation Entertainment, Inc. (NYSE:LYV) on July 31, 2026. Market Context Live Nation Entertainment, Inc.
Read moreRating Change Benchmark analysts reiterated a Buy rating on Live Nation Entertainment, Inc. (NYSE:LYV) on July 31, 2026. Market Context Live Nation Entertainment, Inc.
Read moreRating Change Susquehanna analysts reiterated a Neutral rating on Live Nation Entertainment, Inc. (NYSE:LYV) on July 31, 2026. Market Context Live Nation Entertainment, Inc.
Read moreRating Change Oppenheimer analysts reiterated a Outperform rating on Live Nation Entertainment, Inc. (NYSE:LYV) on July 31, 2026. Market Context Live Nation Entertainment, Inc.
Read moreRating Change Bernstein analysts reiterated a Outperform rating on Live Nation Entertainment, Inc. (NYSE:LYV) on July 31, 2026. Market Context Live Nation Entertainment, Inc.
Read moreRating Change Macquarie analysts reiterated a Outperform rating on AXS SPAC and New Issue ETF (NASDAQ:SPCX) on July 31, 2026. Market Context AXS SPAC and New Issue ETF operates in…
Read moreRating Change HC Wainwright & Co. analysts downgraded Karyopharm Therapeutics Inc. (NASDAQ:KPTI) from Buy to Neutral on July 31, 2026.
Read moreRating Change Piper Sandler analysts reiterated a Overweight rating on Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on July 31, 2026. Market Context Karyopharm Therapeutics Inc.
Read moreRating Change Benchmark analysts reiterated a Buy rating on First Internet Bancorp (NASDAQ:INBK) on July 31, 2026. Market Context First Internet Bancorp operates in the Financial…
Read moreRating Change Piper Sandler analysts reiterated a Neutral rating on First Internet Bancorp (NASDAQ:INBK) on July 31, 2026. Market Context First Internet Bancorp operates in the…
Read moreRating Change Citigroup analysts reiterated a Neutral rating on Xerox Holdings Corporation (NASDAQ:XRX) on July 31, 2026. Market Context Xerox Holdings Corporation operates in the…
Read moreRating Change B. Riley Securities analysts initiated coverage on 4D Molecular Therapeutics, Inc. Common Stock (NASDAQ:FDMT) with a Buy rating on July 31, 2026.
Read moreRating Change Truist Securities analysts reiterated a Buy rating on Employers Holdings, Inc. (NYSE:EIG) on July 31, 2026. Market Context Employers Holdings, Inc.
Read moreRating Change HC Wainwright & Co. analysts reiterated a Neutral rating on CareDx, Inc (NASDAQ:CDNA) on July 31, 2026. Market Context CareDx, Inc operates in the Healthcare sector.
Read moreRating Change HC Wainwright & Co. analysts reiterated a Buy rating on Vericel Corporation (NASDAQ:VCEL) on July 31, 2026. Market Context Vericel Corporation operates in the…
Read moreRating Change Truist Securities analysts reiterated a Buy rating on Vericel Corporation (NASDAQ:VCEL) on July 31, 2026. Market Context Vericel Corporation operates in the…
Read more
